Clinical Study

***Clostridium difficile* Infection and Proton Pump Inhibitor Use in Hospitalized Pediatric Cystic Fibrosis Patients**

John F. Pohl,¹ Raza Patel,¹ Jeffery T. Zobell,² Ellen Lin,² E. Kent Korgenski,³ Kody Crowell,³ Mark W. MacKay,² Aleesha Richman,⁴ Christian Larsen,² and Barbara A. Chatfield⁵

¹ Department of Pediatric Gastroenterology, Hepatology, and Nutrition, Primary Children's Medical Center, University of Utah School of Medicine, Salt Lake City, UT 84113-1103, USA

² Pharmacy Department, Primary Children's Medical Center, Salt Lake City, UT 84113-1100, USA

³ Department of Pediatrics, Primary Children's Medical Center, University of Utah School of Medicine, Salt Lake City, UT 84113-1100, USA

⁴ Pharmacy Department, MaKay-Dee Hospital Center, Intermountain Healthcare, Ogden, UT 84403, USA

⁵ Department of Pediatric Pulmonology, Primary Children's Medical Center, University of Utah School of Medicine, Salt Lake City, UT 84158, USA

Correspondence should be addressed to John F. Pohl, john.pohl@imail.org

Received 9 August 2011; Revised 19 September 2011; Accepted 20 September 2011

Academic Editor: P. Gionchetti

Copyright © 2011 John F. Pohl et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Children with cystic fibrosis (CF) often take proton pump inhibitors (PPIs), which helps improve efficacy of fat absorption with pancreatic enzyme replacement therapy. However, PPI use is known to be associated with *Clostridium difficile*-(*C. diff*-) associated diarrhea (CDAD). We retrospectively evaluated the incidence of *C. diff* infection from all pediatric hospital admissions over a 5-year period at a single tertiary children's hospital. We found significantly more *C. diff*-positive stool tests in hospitalized patients with CF compared to patients with no diagnosis of CF. However, use of a PPI was not associated with an increased risk of CDAD in hospitalized CF patients. In summary, *C. diff* infection is more common in hospitalized pediatric CF patients although PPI use may not be a risk factor for CDAD development in this patient population.

1. Introduction

Cystic fibrosis (CF) is a hereditary multiorgan disease that affects approximately 30,000 people in the United States [1]. Mutation in the *cystic fibrosis transmembrane regulator* (*CFTR*) gene results in impaired ion transport within epithelial cells and leads to mucosal obstruction of exocrine glands, such as in the pancreas [1]. Subsequent hyperviscosity of pancreatic enzyme secretions obstructs the pancreatic ducts and lead to pancreatic fibrosis with poor fat and protein absorption. As a result, CF patients receive pancreatic enzyme replacement therapy (PERT) to aid in fat absorption. Proton pump inhibitors (PPIs) can improve fat absorption and decrease symptoms of steatorrhea in CF patients by inhibiting breakdown of PERT by gastric acid [2, 3].

Therefore, PPI usage is widely used in the CF population [2–5].

Chronic antibiotic use, prolonged hospitalization, and acid-suppressive agents (such as PPIs) are risk factors for developing infection with *Clostridium difficile* (*C. diff*) [6, 7]. *C. diff* can manifest from asymptomatic colonization of the gastrointestinal tract to life-threatening conditions such as pseudomembranous colitis and toxic megacolon [6]. Gastric acidity protects the host against ingested pathogens, and this protection is impaired when acid production is suppressed [7]. Several studies have demonstrated that acid suppression therapy with PPIs may increase the risk of *C. diff*-associated diarrhea (CDAD) [8–12]. We retrospectively evaluated the prevalence of *C. diff* infection in the pediatric CF population at a single pediatric tertiary medical center and tried to de-

TABLE 1: Positive *C. diff* tests for inpatient pediatric patients.

Total tests	8543
All tests in patients with no CF	8302
Positive tests in patients with no CF	1659 (20%)*
All tests in CF patients	241
Positive tests in patients with CF	86 (35.7%)*

* $P < 0.05$.

termine if use of PPI increased the risk of infection in this patient population.

2. Methods

A retrospective chart review occurred over a 5-year period (January 1, 2005, through December 31, 2010) to determine how many tests had been performed for *C. diff* during all inpatient admissions. This data was obtained from the Intermountain Electronic Data Warehouse, Intermountain Primary Children's Medical Center electronic medical record and microbiology lab data. Testing for *C. diff* occurred by toxin ELISA assay or by toxin DNA analysis (Illumigene, Meridian Bioscience, Inc., Cincinnati). Those patients with CF who had a positive *C. diff* stool test during a hospital admission were further analyzed using the Cystic Fibrosis Foundation Patient Registry and the electronic medical record to determine if they had been on a PPI during this admission. Chi-square testing was used to compare prevalence of *C. diff* in hospitalized patients with and without CF, and relative risk analysis was used to determine the risk of *C. diff* in CF patients receiving a PPI [13]. The project was approved by the University of Utah Investigational Review Board.

3. Results

During the 5-year study period, 8543 tests for *C. diff* were performed on hospitalized patients (8302 non-CF controls and 241 CF cases). The prevalence of *C. diff* in controls versus CF patients was statistically significant ($P < 0.05$) with the period prevalence of *C. diff* infection being 20% ($n = 1659$) and 35.7% ($n = 86$), respectively. We were only able to determine the total number of *C. diff* tests that occurred, and testing may have occurred more than once in some patients (Table 1).

Next, we evaluated all CF patients who were hospitalized during this time period using the Cystic Fibrosis Foundation Patient Registry to determine which patients were on a PPI. We found 215 total patients which were different than the total number of patients found using the electronic medical record (241 patients). Of these 215 patients, 140 were on no PPI and 57 of these patients (40.7%) had CDAD. There were 75 patients who were on a PPI, and 30 patients (40%) had CDAD. A relative risk analysis was not significant suggesting that the risk of developing CDAD in CF patients was equal regardless of PPI exposure (Table 2).

TABLE 2: CDAD in CF patients with/without PPI use.

Total CF patients admitted to hospital	215
CF patients on PPI and CDAD	30 (40%)*
CF patients on PPI and no CDAD	45
CF patients on no PPI and CDAD	57 (40.7%)*
CF patient on no PPI and no CDAD	83

*Relative risk 0.98 (95% confidence interval 0.698 to 1.382), $P = 0.91$.

4. Discussion

This retrospective study evaluated both the prevalence of *C. diff* infection in CF pediatric patients during inpatient admission compared to patients without CF and the risk of CDAD in CF patients receiving a PPI. We found that significantly more patients had positive *C. diff* testing during hospital admission with CF compared to non-CF patients. Unlike CF pediatric patients, the typical hospitalized patients with CDAD in the United States hospitals are elderly, female, and have associated sepsis [14]. Antibiotic use is also associated with CDAD in hospitalized patients [15].

It is known that the asymptomatic carriage rate of *C. diff* in CF can be as high as 50%, and associated factors leading to CDAD in hospitalized CF patients potentially could include risk factors such as recurrent hospitalization, prolonged intravenous antibiotic use, and lack of colonization with *Lactobacillus* species and other bacteria that may have inhibitory effects on the growth of *C. diff* [16–18]. Other diseases associated with *C. diff*, such as Crohn's disease, occur more frequently in CF patients [19]. Additionally, CF genotypes, such as N1303K, are associated with more severe clinical presentations of CDAD [20].

PPI use has been associated with an increased risk of CDAD, especially in the elderly [21]. The effect is presumable due to gastric acid inhibition by PPIs, and the risk of infection is increased with escalating PPI dosing [22]. Interestingly, we saw no increased incidence of CDAD in CF pediatric patients, regardless of PPI usage status. The cause of this finding is unknown. A prior study looking at the risk of developing CDAD in a community setting did not find PPI usage associated with an increased risk of CDAD; however, other proposed risk factors for disease transmission in this population included person-to-person transmission and remote health care exposures [23]. Bacterial overgrowth is not always associated with intestinal inflammation in some CF patients, suggesting that there may be other microbiome, genetic, or inflammatory pathways that may explain our finding [24]. It is the clinical practice at our institution to place all CF patients on *Lactobacillus* GG at time of admission and throughout the intravenous antibiotic course. This treatment is not typically continued upon completion of an antibiotic treatment unless the patient has been diagnosed with CDAD during hospitalization. However, it is not known if such therapy is effective in preventing CDAD in this patient population [25].

There are weaknesses in this study. This study is retrospective and consists of data from a single tertiary medical center. In our review of the electronic medical record of

all pediatric inpatient admissions, we could not determine if testing for *C. diff* occurred because of CDAD, although asymptomatic hospitalized patients presumably would not be tested for this pathogen. However, we were able to determine CDAD in hospitalized CF patients using the Cystic Fibrosis Foundation Patient Registry. Finally, we did not evaluate for other potential causes that would explain the lack of difference in CDAD regardless of PPI use in the CF population, although we did evaluate a large number of pediatric CF inpatient admissions over a 5-year period of time.

5. Conclusion

We found significantly more *C. diff* infections in hospitalized pediatric patients with CF compared to patients hospitalized for other medical reasons. PPI use by CF patients appears not to be associated with an increased risk of developing CDAD. We encourage judicious use of antibiotics as well as simple techniques in preventing disease transmission, such as good handwashing to prevent CDAD in CF pediatric patients. We recommend a prospective, multicenter study to corroborate these findings and to determine what specific risk factors in the CF pediatric population predispose to *C. diff* infection such as CF genotype, length of PPI usage, patient age, and presence of other comorbidities such as inflammatory bowel disease.

Acknowledgments

Dr. J. F. Pohl has received funding for investigator-initiated funding from Eurand Pharmaceuticals (Yardley, Pa) and Takeda Pharmaceuticals (Deerfield, Ill).

References

- [1] K. J. Novak, "Cystic fibrosis," in *Pharmacotherapy Principles and Practice*, M. A. Chisholm-Burns, B. G. Wells, and T. L. Schwinghammer, Eds., McCraw-Hill, New York, NY, USA, 2008.
- [2] H. Hendriks, B. Kreel, and P. Forget, "Effects of therapy with lansoprazole on intestinal permeability and inflammation in young cystic fibrosis patients," *Journal of Pediatric Gastroenterology and Nutrition*, vol. 33, no. 3, pp. 260–265, 2001.
- [3] M. Proesmans and B. K. Omeprazole, "Omeprazole, a proton pump inhibitor, improves residual steatorrhea in cystic fibrosis patients treated with high dose pancreatic enzymes," *European Journal of Pediatrics*, vol. 162, no. 11, pp. 760–763, 2003.
- [4] J. F. Pohl, "Nutrition in cystic fibrosis," *Practical Gastroenterology*, vol. 34, no. 3, pp. 20–27, 2010.
- [5] T. Tran, A. van den Neucker, J. Hendriks, P. Forget, and P. P. Forget, "Effects of a proton-pump inhibitor in cystic fibrosis," *Acta Paediatrica*, vol. 87, no. 5, pp. 553–558, 1998.
- [6] L. Sayedy, D. Kothari, and R. Richards, "Toxic megacolon associated *Clostridium difficile* colitis," *World Journal of Gastrointestinal Endoscopy*, vol. 2, pp. 293–297, 2010.
- [7] S. Dial, J. Delaney, A. Barkun, and S. Suissa, "Use of gastric acid-suppressive agents and the risk of community-acquired *Clostridium difficile*-associated disease," *Journal of the American Medical Association*, vol. 294, no. 23, pp. 2989–2995, 2005.
- [8] J. Leonard, J. K. Marshall, and P. Moayyedi, "Systematic review of the risk of enteric infection in patients taking acid suppression," *American Journal of Gastroenterology*, vol. 102, no. 9, pp. 2047–2056, 2007.
- [9] S. Dial, K. Allrasadi, C. Manoukian et al., "Risk of *Clostridium difficile* diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies," *Canadian Medical Association Journal*, vol. 17, no. 1, pp. 33–38, 2004.
- [10] K. Yearsley, L. Gilby, A. Ramadas, E. M. Kubiak, D. L. Fone, and M. C. Allison, "Proton pump inhibitor therapy is a risk factor for *Clostridium difficile*-associated diarrhoea," *Alimentary Pharmacology and Therapeutics*, vol. 24, no. 4, pp. 613–619, 2006.
- [11] R. Cadle, M. Mansouri, L. Logan, D. R. Kudva, and D. M. Musher, "Association of proton-pump inhibitors with outcomes in *Clostridium difficile* colitis," *American Journal of Health-System Pharmacy*, vol. 64, no. 22, pp. 2359–2363, 2007.
- [12] S. Jayatilaka, R. Shakov, R. Eddi, G. Bakaj, W. J. Baddoura, and V. A. DeBari, "*Clostridium difficile* infection in an urban medical center: five-year analysis of infection rates among adult admissions and association with the use of proton pump inhibitors," *Annals of Clinical and Laboratory Science*, vol. 37, no. 3, pp. 241–247, 2007.
- [13] K. J. Preacher, "Calculation for the chi-square test: an interactive calculation tool for chi-square tests of goodness of fit and independence [Computer software]," <http://quantpsy.org/>.
- [14] A. Elixhauser and M. Jhung, *Clostridium difficile*-associated disease in U.S. hospitals, 1993–2005: Statistical brief #50. Healthcare Cost and Utilization Project Statistical Briefs [Internet]. Agency for Health Care Policy and Research (US): 2006–2008.
- [15] N. Werner, M. Hecker, A. Sethi, and C. J. Donskey, "Unnecessary use of fluoroquinolone antibiotics in hospitalized patients," *BMC Infectious Diseases*, vol. 11, article 187, 2011.
- [16] C. Pokorny, B. Bye, C. Macleod, and W. S. Selby, "Antibiotic-associated colitis and cystic fibrosis," *Digestive Diseases and Sciences*, vol. 37, no. 9, pp. 1464–1468, 1992.
- [17] S. L. Peach, S. P. Borriello, and H. Gaya, "Asymptomatic carriage of *Clostridium difficile* in patients with cystic fibrosis," *Journal of Clinical Pathology*, vol. 39, no. 9, pp. 1013–1018, 1986.
- [18] C. P. Kelly, C. Pothoulakis, and J. T. LaMont, "*Clostridium difficile* colitis," *New England Journal of Medicine*, vol. 330, no. 4, pp. 257–262, 1994.
- [19] H. Chaun, "Colonic disorders in adult cystic fibrosis," *Canadian Journal of Gastroenterology*, vol. 15, no. 9, pp. 586–590, 2001.
- [20] J. Rivlin, A. Lerner, A. Augarten, M. Wilschanski, E. Kerem, and M. A. Ephros, "Severe *Clostridium difficile*-associated colitis in young patients with cystic fibrosis," *Journal of Pediatrics*, vol. 132, no. 1, pp. 177–179, 1998.
- [21] J. Kim, K. Lee, J. Jeong et al., "Proton pump inhibitors as a risk factor for recurrence of *Clostridium-difficile*-associated diarrhea," *World Journal of Gastroenterology*, vol. 16, no. 28, pp. 3573–3577, 2010.
- [22] M. Howell, V. Novack, P. Grgurich et al., "Iatrogenic gastric acid suppression and the risk of nosocomial *Clostridium difficile* infection," *Archives of Internal Medicine*, vol. 170, no. 9, pp. 784–790, 2010.
- [23] S. Naggie, B. Miller, K. Zuzak et al., "A case-control study of community-associated *Clostridium difficile* infection: no role for proton pump inhibitors," *American Journal of Medicine*, vol. 124, no. 3, pp. 276-e1–276-e7, 2011.

- [24] A. Lisowska, E. Mdry, A. Pogorzelski, J. Szydlowski, A. Radzikowski, and J. Walkowiak, "Small intestine bacterial overgrowth does not correspond to intestinal inflammation in cystic fibrosis," *Scandinavian Journal of Clinical and Laboratory Investigation*, vol. 70, no. 5, pp. 322–326, 2010.
- [25] M. Segarra-Newnham, "Probiotics for *Clostridium difficile* associated diarrhea: focus on *Lactobacillus rhanosus* GG and *Saccharomyces boulardii*," *Annals of Pharmacotherapy*, vol. 41, no. 7-8, pp. 1212–1221, 2007.